Evidence map›Paper›PMID 38794202›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

The Synergistic Effect of N2 and N7 Modifications on the Inhibitory Efficacy of mRNA Cap Analogues.

Karol Kurpiejewski, Karolina Piecyk, Maciej Lukaszewicz, Karol Kamel, Kazimierz Chmurski, Sebastian Kmiecik, Marzena Jankowska-Anyszka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Application of Mammalian Nudix Enzymes to Capped RNA Analysis.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Karol KurpiejewskiFaculty of Chemistry, University of Warsaw, 02-093 Warsaw, Poland.ORCID 0000-0002-0982-081X
Karolina PiecykFaculty of Chemistry, University of Warsaw, 02-093 Warsaw, Poland.
Maciej LukaszewiczDivision of Biophysics, Institute of Experimental Physics, University of Warsaw, 02-093 Warsaw, Poland.
Karol KamelInstitute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.ORCID 0000-0002-9252-2003
Kazimierz ChmurskiFaculty of Chemistry, University of Warsaw, 02-093 Warsaw, Poland.
Sebastian KmiecikBiological and Chemical Research Centre, Faculty of Chemistry, University of Warsaw, 02-089 Warsaw, Poland.ORCID 0000-0001-7623-0935
Marzena Jankowska-AnyszkaFaculty of Chemistry, University of Warsaw, 02-093 Warsaw, Poland.

Funding

The National Science Centre, Poland UMO/2018/31/B/ST5/03544
6 · The paper itself

Abstract

In the fight against cancer, researchers have turned their attention to the eukaryotic initiation factor eIF4E, a protein whose increased level is strongly correlated with the development and progression of various types of cancer. Among the numerous strategies devised to tackle eIF4E overexpression, the use of 5' end mRNA cap analogues has emerged as a promising approach. Here, we present new candidates as potent m

Indexed as

cap analoguescap-dependent translationinhibitormRNAnucleotide

Identifiers

PMID38794202
PMCPMC11123931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.